Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sign Up to like & getrecommendations! Published in 2019 at "Nature Medicine"
DOI: 10.1038/s41591-019-0474-7
Abstract: Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as… read more here.
Keywords: cobimetinib vemurafenib; braf mek; vemurafenib braf; braf ... See more keywords